|Hyperphosphatemia CME Info|
Consequences of Hyperphosphatemia:
Are We Accepting the Unacceptable?
University of Minnesota
CME Internet Course
Hyperphosphatemia is a nearly universal condition in patients with kidney disease, putting them at significant risk for secondary hyperparathyroidism, metastatic calcification, and renal bone disease.
This symposium will provide an overview of the clinical complications of poor phosphorus and calcium balance and present evidence regarding the importance of establishing a new, lower Ca x P target. Speakers will address altering management practices to achieve more acceptable patient outcomes.
Program Objectives Include:
- Express the primary role of phosphorus in causing elevated levels of PTH and emphasize the life-threatening consequences of uncontrolled PTH, phosphorus, and Ca x P
- Outline the critical nature of correcting disturbances in acid base to restore calcium balance and lower Ca x P
- Discuss the evidence demonstrating that current management practices and Ca x P targets are detrimental for patient survival
Faculty Eduardo Slatopolsky, MD
Professor of Renal Diseases in Medicine
Washington University, St. Louis, MO
David Bushinsky, MD
Chief of Nephrology
University of Rochester Medical Center, Rochester, NY
Glenn Chertow, M.D., M.P.H.
Professor of Nephrology,
University of California at San Francisco
San Francisco, CA
Earning CME Credit
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Minnesota and Medical Media Associates, Inc. The University of Minnesota is accredited by the ACCME to provide continuing medical education for physicians. The University of Minnesota designates this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity. This activity was planned and produced in accordance with ACCME Essentials. Credit designation expires March, 2001.
This program was presented as a satellite symposium at the 1999 American Society of Nephrology meeting in Miami. Any physician who earned CME credits at this symposium is not eligible to receive CME credits for this Internet program.
This Internet program is supported by an unrestricted educational grant from Genzyme Therapeutics, and administered by Medical Education Institute.
To earn credit for viewing the lectures, please print out and complete the enrollment, evaluation, and posttest forms and mail them to:
University of Minnesota
Office of Continuing Medical Education
615 Washington Ave. SE
Minneapolis, MN 55414
or FAX to (612) 626-7766.
Conflict of Interest, Trade Name, and Nonindicated Use Information